Jubilant Pharmova LtdQ1 FY26Pharmaceuticals & Biotechnology

Jubilant Pharmova Ltd

Q1 FY26 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→FY2027 growth momentum expected to strengthen, with low double-digit consolidated business growth anticipated.
→Radiopharma revenues expected to be temporarily impacted in H1 FY2027 due to supply shortage of high-margin SPECT products (~$14 million revenue impact), normalizing in H2 FY2027.
→Ruby-Fill® revenue continuing rapid expansion (~30%+ growth), with increasing market size, share, and pricing.
→Allergy business growing faster than US market rates (3-5%), driven by non-US markets and increased US market share.
→Line 3 tech transfer revenues expected at $60-$80 million in FY2027, with margins improving post full utilization.
→Montreal site expected to reduce losses in FY2028 and to start generating revenues from Line 5 from FY2029.
→FY2028 radiopharma expected to see margin improvement as supply issues are resolved.
→No major capex planned beyond existing Line 3, 4, 5, and PET manufacturing projects for next 12-18 months.

Margin guidance

Category 3

→FY2027 growth momentum expected to strengthen across businesses.
→EBITDA margin for FY2027 will be a "story of two halves":
→ - H1 FY2027 margins impacted due to supply shortage of high-margin SPECT products at Montreal facility (revenue impact approx. $14 million).
→ - H2 FY2027 margins expected to improve to 17%-18% as Montreal production stabilizes, reflecting normalized margins going into FY2028.
→Consolidated business expected to grow in low double digits in FY2027.
→Radiopharma margins targeted at 38%-40% in FY2027.
→FY2028 to see meaningful reduction in losses from Montreal operations and recovery driven by new product launches including MIBG and pipeline.
→Free cash flow expected to improve post commercialization of Spokane Line 3/Line 4 products from FY2027 onwards aiding debt reduction.
→Committed to achieving net debt zero by FY2030.
→Allergy business growth driven by market expansion and non-US market growth; US allergy market growth limited to ~3%-5%.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Jubilant Pharmova Ltd and 1,400+ other companies.

Fundraise plans

- The company is currently focused on utilizing existing capital for ongoing projects like Spokane Line 4, Montreal Line 5, and PET pharmacies, with a capex in FY2027 expected to be similar to FY2026 (around Rs.1,668 Crores). - There is no indication of any new fundraising planned through debt or equity in the near term; capital allocation is guided by ROCE thresholds and immediate investments are largely committed. - Management expressed commitment to reducing net debt starting FY2028 and achieving net debt zero by FY2030. - The focus is on generating free cash flows from commercialization of products at Line 3 and Line 4 to help deleverage, rather than raising fresh funds. Therefore, no explicit plans for new debt or equity fundraising were disclosed during the call.

Order book

The provided transcript from Jubilant Pharmova Limited's Q4 and FY2026 earnings webinar does not explicitly mention current or expected orderbook or pending orders in detail. However, key insights related to business growth and product pipelines include: - The CDMO Sterile Injectables business has about 10+ products in tech transfer on Line 3, with commercial production expected late FY2027, generating $60-$80 million revenue. - Approximately 80% of these Line 3 products are complex biologics, commanding premium pricing. - Ruby-Fill® franchise is rapidly expanding in market size and share, contributing to increasing recurring revenues. - Allergy business growth driven by increased market share and expansion into non-US markets. - Radiopharma's Montreal facility production is stabilizing; first half FY2027 margins impacted temporarily due to supply shortages. - Significant capex ongoing for Spokane Line 4, Montreal Line 5, and PET pharmacies supporting future growth. No direct quantitative orderbook or pending order value disclosures were provided.

Capex plans

Yes

→FY2026 capex was Rs.1,668 Crores; FY2027 capex expected to be similar.
→Key ongoing projects:
→ - Spokane Line 4: $34 million remaining of $200 million total.
→ - Montreal Line 5: $87 million pending of total ongoing investment.
→ - PET pharmacies: $50 million pending with $22 million spent so far.
→No additional capex envisioned beyond these projects for next 12-18 months.
→Capital allocation is strictly based on crossing ROCE thresholds.
→These projects focus on expanding sterile injectable CDMO capacity and PET manufacturing.
→Once these projects complete and Line 3 production ramps up, free cash flow generation will improve, enabling debt reduction.
→Target to achieve net debt zero by FY2030 with debt reduction starting FY2028 onwards.

How does Jubilant Pharmova Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Jubilant Pharmova Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Unlock with Pro

Want more stocks like Jubilant Pharmova Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio